Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism

Jiaxin Hu, Jing Liu, David R. Corey

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity. An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact. We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles. Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells. Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.

Original languageEnglish (US)
Pages (from-to)1183-1188
Number of pages6
JournalChemistry and Biology
Volume17
Issue number11
DOIs
StatePublished - Nov 24 2010

Fingerprint

RNA Interference
MicroRNAs
Alleles
Huntington Disease
RNA
Toxicity
Complementary RNA
Messenger RNA
Proteins
Inhibition (Psychology)
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Drug Discovery
  • Molecular Biology
  • Clinical Biochemistry
  • Molecular Medicine
  • Pharmacology

Cite this

Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. / Hu, Jiaxin; Liu, Jing; Corey, David R.

In: Chemistry and Biology, Vol. 17, No. 11, 24.11.2010, p. 1183-1188.

Research output: Contribution to journalArticle

@article{5a3f59f56b4f4cfcbef7ea978100e491,
title = "Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism",
abstract = "Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity. An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact. We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles. Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells. Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.",
author = "Jiaxin Hu and Jing Liu and Corey, {David R.}",
year = "2010",
month = "11",
day = "24",
doi = "10.1016/j.chembiol.2010.10.013",
language = "English (US)",
volume = "17",
pages = "1183--1188",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism

AU - Hu, Jiaxin

AU - Liu, Jing

AU - Corey, David R.

PY - 2010/11/24

Y1 - 2010/11/24

N2 - Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity. An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact. We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles. Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells. Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.

AB - Inhibiting expression of huntingtin (HTT) protein is a promising strategy for treating Huntington's disease (HD), but indiscriminant inhibition of both wild-type and mutant alleles may lead to toxicity. An ideal silencing agent would block expression of mutant HTT while leaving expression of wild-type HTT intact. We observe that fully complementary duplex RNAs targeting the expanded CAG repeat within HTT mRNA block expression of both alleles. Switching the RNAi mechanism toward that used by miRNAs by introducing one or more mismatched bases into these duplex RNAs leads to potent (<10 nM) and highly selective (>30-fold relative to wild-type HTT) inhibition of mutant HTT expression in patient-derived cells. Potent, allele selective inhibition of HTT by mismatched RNAs provides a new option for developing HD therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=78649359013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649359013&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2010.10.013

DO - 10.1016/j.chembiol.2010.10.013

M3 - Article

C2 - 21095568

AN - SCOPUS:78649359013

VL - 17

SP - 1183

EP - 1188

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 11

ER -